The increasing interest in potent weight management has resulted in considerable investigation into novel treatments. Currently, Retatrutide, a twin-action hormone and glucagon-like peptide-1 (GLP-1) receptor agonist , has shown encouraging results in patient trials, suggesting potential for sign